Yong Cang
Chief Scientific Officer & Co-founder Degron Therapeutics
Yong Cang, PhD, is the Co-founder and CSO of Degron Therapeutics. He is a scientific leader in targeted protein degradation, ubiquitin ligase biology and cancer immunotherapy with more than 30 publications in top biomedical journals. Dr. Cang pioneers novel molecular glue degrader discovery strategies, with a focus on screening approach development and mechanistic understanding of interactions between molecular glue drugs, ubiquitin ligases and neo-substrates. Dr. Cang is a professor and head of the Laboratory of Targeted Protein Degradation in the School of Life Science and Technology of ShanghaiTech University. He previously was an assistant professor in the NCI-designated Cancer Center of Sanford Burnham Prebys Medical Discovery Institute and a professor of Zhejiang University. Dr. Cang consulted for pharmaceutical industry and venture funds.
Dr. Cang received a BS from Fudan University and a PhD in Molecular Genetics from the Albert Einstein College of Medicine. He completed his postdoctoral training with Professor Stephen Goff at Columbia University and HHMI.
Seminars
- Exploring mechanistic insights into substrate recruitment and release to reveal how molecular glue degraders orchestrate target engagement for improved selectivity and therapeutic precision
- Demonstrating advanced experimental approaches that uncover dynamic interactions within glue-induced complexes to accelerate rational design and optimize degrader performance
- Translating structural and kinetic learnings into predictive models that streamline discovery workflows and enable faster progression of innovative gluebased therapies
- Understanding Korean venture capital expectations to tailor fundraising strategies, attract competitive capital and enable sustainable biotech scaling
- Identifying how recent deals highlight investor priorities for emerging modalities including novel ligases, non-oncology-targeted degraders, and DACs to guide platform positioning and increase funding success
- Examining how early-stage proof-of-concept studies validate technology, strengthen investor confidence, and accelerate pharma partnership commitments
- Discussing how to structure successful biotech–pharma–academia collaborations in South Korea to balance expectations and maximize the translational speed of your TPD candidate
